Specialty drugs expected to account for 40% of total prescription spending by 2016, according to Catamaran Corporation.
While the overall benefits of the Affordable Care Act (ACA) are still hotly debated, there is little doubt the landmark legislation will lead to a boon for the pharmaceutical industry and the specialty drug market, according to the latest drug trend update from the Catamaran Corporation.
Catamaran, which provides pharmacy benefit management (PBM) services and technology, recently released a trend report updated for the first half of 2014 that calls for an upward trajectory for pharmacy spending due to the combined impact of health care reform and a robust drug pipeline. Technological advances and a growing demand for specialty therapies is expected to drive specialty medications to account for approximately 40% of all pharmacy spending by 2016.
“The impact of health care reform will become readily apparent across pharmacy purchasing and benefits,” the report states. “US spending on prescription drugs is estimated to increase in the retail space by $227 billion between 2010 and 2020.”
Read the full story here: http://bit.ly/1uncrGT
Source: Specialty Pharmacy Times
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More